Source link : https://www.newshealth.biz/health-news/fda-approves-nemolizumab-for-prurigo-nodularis/
On August 13, 2024, the US Food and Drug Administration (FDA) approved nemolizumab for the treatment of adults with prurigo nodularis (PN). A first-in-class monoclonal antibody specifically designed to inhibit interleukin (IL)-31 signaling, nemolizumab, will be available in a pre-filled pen for subcutaneous injection and will be marketed as Nemluvio. It is currently under FDA […]
Author : News Health
Publish date : 2024-08-13 15:30:30
Copyright for syndicated content belongs to the linked Source.
Categories